SCHEMBL3206530

SCHEMBL3206530

O=C(O)CSC(=S)Oc1cc(F)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
CYP2D6 P10635 1/20 0.39
PKM P14618 1/20 0.37
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
AKR1A1 P14550 1/20 0.35
AKR1B1 P15121 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.34
GRK6 P43250 1/20 0.34
FFAR1 O14842 4/20 0.34
FFAR4 Q5NUL3 4/20 0.34
CXCL8 P10145 1/20 0.34
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
FABP4 P15090 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206539 0.74 CES2 (0.50) ALDH1A1PKMCES2CES1KMT2A
SCHEMBL15763924 0.71 CYP4F2 (0.45) ALDH1A1CYP4F2CYP4A11CES2CES1
SCHEMBL28015642 0.69 CES2 (0.45) ALDH1A1CYP4F2CYP4A11CES2CES1
SCHEMBL1991907 0.69 CYP4F2 (0.64) ALDH1A1CYP4F2CYP4A11CES2CES1
SCHEMBL5706864 0.69 CA3 (0.40) ALDH1A1CYP4F2CYP4A11CES2CES1
SCHEMBL6146229 0.68 MAPT (0.42) ALDH1A1CYP4F2CYP4A11CES2CES1
SCHEMBL1997019 0.68 CYP4F2 (0.46) CYP4F2CYP4A11CES2CES1KMT2A
SCHEMBL27569618 0.68 CYP4F2 (0.42) ALDH1A1PKMCYP4F2CYP4A11CES2
SCHEMBL10180883 0.67 KMT2A (0.56) ALDH1A1PKMMAPTKMT2A
SCHEMBL3267027 0.67 LMNA (0.51) PKMPTGDR2FFAR1FFAR4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324257-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2012-12-04 US disclosed
US-20100041719-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041719-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIF18B ALDH1A1 2961/4885CYP2D6 4482/4885PKM 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.